1.Study on the cytotoxic activity of platinum(II) complexes of (1R,2R)-N(1)-cyclopentyl-1,2-cyclohexanediamine with substituted malonate derivatives.
Zhou Z1, Chen F2, Xu G2, Gou S3. Bioorg Med Chem Lett. 2016 Jan 15;26(2):322-7. doi: 10.1016/j.bmcl.2015.12.019. Epub 2015 Dec 8.
Three platinum(II) complexes of (1R,2R)-N(1)-cyclopentyl-1,2-cyclohexanediamine with malonate derivatives were designed, synthesized and spectrally characterized. MTT assay showed that the complexes possessed positive cytotoxic effect on the four human solid tumor cell lines. Among the complexes, complex 2 demonstrated the strongest cytotoxic activity compared to cisplatin and oxaliplatin against HepG2 cell line (IC50=3.04μM). Furthermore, the results of gel electrophoresis revealed that complex 2 interacted with DNA in a different mode from that of cisplatin. Mechanism studies of cell proliferation inhibition and cellular uptake indicated that complex 2 entered HepG2 cell more efficiently than cisplatin, exhibited massive G2 accumulation and then induced apoptosis.
2.Antitumor platinum(II) complexes of N-monoalkyl-1R, 2R-diaminocyclohexane derivatives with alkyl groups as hindrance.
Sun Y1, Yin R, Gou S, Zhaojian. J Inorg Biochem. 2012 Jul;112:68-76. doi: 10.1016/j.jinorgbio.2012.03.003. Epub 2012 Mar 17.
A number of platinum (II) complexes, characteristic of (1R,2R)-N(1)-alkyl-1,2-diaminocyclohexane derivatives as carrier ligands, were designed, synthesized and characterized, where the alkyl group serving as hindrance is a 1-butyl, 2-methylpropyl or 2-butyl moiety, respectively. In vitro biological evaluation of these platinum complexes revealed that their antitumor activity had a close relationship with the shape of alkyl groups. In vivo antitumor study indicated that complex 1c, [(1R,2R)-N(1)-(2-butyl)-1,2-cyclohexanediamine-N,N'] (oxalato-O,O')platinum (II), possessed rather high antitumor effect and low toxicity compared with cisplatin and oxaliplatin. Antitumor mechanism of 1c has been tentatively studied, which might be different from that of cisplatin and oxaliplatin.
